检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:寿延红[1] 陈颖[1] 冯加纯[1] 张淑琴[1] 饶明俐[1]
机构地区:[1]吉林大学第一医院神经内科
出 处:《中风与神经疾病杂志》2001年第3期139-140,共2页Journal of Apoplexy and Nervous Diseases
摘 要:目的 观察刺五加对蛛网膜下腔出血 (SAH)患者血浆内皮素 (ET)的作用 ,进一步探讨刺五加防治SAH后脑血管痉挛 (CVS)的作用机制。方法 将 SAH患者 44例 ,随机分为刺五加组 (2 0例 )和 SAH对照组 (2 4例 ) ,应用放射免疫分析方法 ,测定刺五加组不同时期血浆中 ET含量 ,并与 SAH对照组和正常对照组 (2 0例 )比较。结果 SAH对照组于用药前及用药后 2 h、7d、14d血浆 ET含量分别为 6 8.38± 15 .41、6 0 .45± 11.35、5 6 .83±9.35、5 5 .2 5± 8.2 1,均明显高于正常对照组 41.12± 6 .37(P<0 .0 1,P<0 .0 5 ) ;刺五加组用药后 2 h、7d和 14d血浆ET含量分别为 42 .30± 13.45、46 .5 2± 10 .36、48.31± 9.17,与 SAH对照组同期比较 ,明显降低 (P<0 .0 1,P<0 .0 5 ) ;刺五加组用药后不同时期血浆 ET含量明显低于用药前 (P<0 .0 1)。结论 刺五加能明显降低 SAH后增高了的血浆 ET水平 ,从而预防和治疗 SAH后 CVS,保障脑组织的血液供给。Objective To study the influence of Acanthopanax Senticosus Harms (AS) on the content of the plasma endothelin (ET) in the patients with subarachnoid hemorrhage(SAH),and discuss the mechanism of prevention and treatment of cerebral vasospasm (CVS) after SAH with AS. Methods 44 cases of SAH were divided into AS group (20 cases) and SAH control group (24 cases) randomly. Radioimmuno assay were used to measure the contents of plasma ET at different times. The contents of plasma ET in AS group were compared with those in SAH control group and normal control group (20 cases). Results The contents of plasma ET in SAH control group were significantly higher than those in normal control group (P<0.01,P<0.05) at different times. After treatment with AS,the contents of plasma ET in AS group were significantly lower than those in SAH control group(P<0.01,P<0.05),and they were also significantly lower than those in AS group before treatment(P< 0.01 ). Conclusion AS can prevent and treat the CVS after SAH,and ensure the blood supply of cerebral tissue by decreasing the content of plasma ET.
分 类 号:R743.35[医药卫生—神经病学与精神病学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:3.142.243.141